

MSDS FOR REPLICATION-DEFECTIVE ADENO-ASSOCIATED VIRAL (AAV) VECTORS (Biosafety Level 2)

Cultures of replication defective AAV vectors are non-infectious and are not hazardous materials as defined by OSHA 1919.1200. However, these materials are produced in cells where there is the possibility of recombination to form wild type virus. As such, they should be handled as potentially infectious material.

Description:

AAV vectors consist of recombinant transgene sequences (e.g., marker or human genes) flanked by the AAV inverted terminal repeats. The removal of the majority of viral structural genes renders the vector replication-defective and dependent on an AAV helper virus. AAV cultures are normally provided as purified viral particles in phosphate buffered saline at a concentration of up to 1×10^{13} particles/ml. The viral stock consists of particles containing the vector genome (full capsids) and a variable number of empty viral capsids in PBS. Other trace components present include, but are not limited to, inorganic salts, vitamins and other nutrients, and human cellular proteins, carbohydrates, amino acids, and fats. The material is normally shipped and stored frozen.

SECTION I

Hazardous Ingredients

None

SECTION II

Physical Data

Liquid or frozen particle suspensions

SECTION III

Health Hazards

AAV cultures are not known to cause any diseases in humans or animals

SECTION IV

Fire and Explosion

None

SECTION V

Reactivity

Stable. Will enter mammalian cells in the presence of adenovirus and can integrate into host cell DNA

SECTION VI**Method of Disposal**

Spill: Contain spill and decontaminate the area using a disinfectant such as chlorine bleach (10% f.c.), Wescodyne, or detergent-based disinfectant.

Waste Disposal: Dispose of viral stock by autoclaving at 121°C for 30-45 minutes
Dispose of infected liquid cultures by decontamination with chlorine bleach (10% f.c.) for 10 minutes and then dispose of in sink.
Dispose of infected animal carcasses or tissues by incineration

Follow all Federal, State, and Local regulations.

SECTION VII**Special Protective Information**

Handle as biohazardous material under Biosafety Level 2 containment

SECTION VIII**Special Precautions or Comments**

The Gene Therapy Center recommends that all AAV vectors and cultures be handled by qualified microbiologists using appropriate safety procedures and precautions. Detailed discussions of laboratory safety procedures are provided in **Laboratory Safety: Principles and Practice** (Fleming et al., ASM Press, Washington D.C., 1995), and in the U.S. Government Publication, **Biosafety in Microbiological and Biomedical Laboratories** (CDC, 1999). This and other publications are available at the Centers for Disease Control Office of Health and Safety's website at <http://www.cdc.gov/od/ohs/biosfty/bmb14/bmb14toc.htm>

Information on the classification of human etiologic agents on the basis of hazard can be found as Appendix B in the NIH **Guidelines for Research Involving Recombinant DAN Molecules** at <http://www.grants.nih.gov/grants/policy/recombinentdnaguidelines.htm>

The above information is accurate to the best of our knowledge. All materials and mixtures may present unknown hazards and should be used with caution. The user should exercise independent judgment as to the hazards based on all sources of information available. The Gene Therapy Center shall not be held liable for any damage resulting from the handling or use of the above product